126 related articles for article (PubMed ID: 27191720)
21. MicroRNA expression signature of castration-resistant prostate cancer: the microRNA-221/222 cluster functions as a tumour suppressor and disease progression marker.
Goto Y; Kojima S; Nishikawa R; Kurozumi A; Kato M; Enokida H; Matsushita R; Yamazaki K; Ishida Y; Nakagawa M; Naya Y; Ichikawa T; Seki N
Br J Cancer; 2015 Sep; 113(7):1055-65. PubMed ID: 26325107
[TBL] [Abstract][Full Text] [Related]
22. Stromal factors involved in human prostate cancer development, progression and castration resistance.
Eiro N; Fernandez-Gomez J; Sacristán R; Fernandez-Garcia B; Lobo B; Gonzalez-Suarez J; Quintas A; Escaf S; Vizoso FJ
J Cancer Res Clin Oncol; 2017 Feb; 143(2):351-359. PubMed ID: 27787597
[TBL] [Abstract][Full Text] [Related]
23. High levels of the AR-V7 Splice Variant and Co-Amplification of the Golgi Protein Coding YIPF6 in AR Amplified Prostate Cancer Bone Metastases.
Djusberg E; Jernberg E; Thysell E; Golovleva I; Lundberg P; Crnalic S; Widmark A; Bergh A; Brattsand M; Wikström P
Prostate; 2017 May; 77(6):625-638. PubMed ID: 28144969
[TBL] [Abstract][Full Text] [Related]
24. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
25. Androgen Receptor Variant AR-V9 Is Coexpressed with AR-V7 in Prostate Cancer Metastases and Predicts Abiraterone Resistance.
Kohli M; Ho Y; Hillman DW; Van Etten JL; Henzler C; Yang R; Sperger JM; Li Y; Tseng E; Hon T; Clark T; Tan W; Carlson RE; Wang L; Sicotte H; Thai H; Jimenez R; Huang H; Vedell PT; Eckloff BW; Quevedo JF; Pitot HC; Costello BA; Jen J; Wieben ED; Silverstein KAT; Lang JM; Wang L; Dehm SM
Clin Cancer Res; 2017 Aug; 23(16):4704-4715. PubMed ID: 28473535
[No Abstract] [Full Text] [Related]
26. A hnRNP K⁻AR-Related Signature Reflects Progression toward Castration-Resistant Prostate Cancer.
Capaia M; Granata I; Guarracino M; Petretto A; Inglese E; Cattrini C; Ferrari N; Boccardo F; Barboro P
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29966326
[TBL] [Abstract][Full Text] [Related]
27. lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.
Gu P; Chen X; Xie R; Han J; Xie W; Wang B; Dong W; Chen C; Yang M; Jiang J; Chen Z; Huang J; Lin T
Mol Ther; 2017 Aug; 25(8):1959-1973. PubMed ID: 28487115
[TBL] [Abstract][Full Text] [Related]
28. The ErbB family and androgen receptor signaling are targets of Celecoxib in prostate cancer.
Brizzolara A; Benelli R; Venè R; Barboro P; Poggi A; Tosetti F; Ferrari N
Cancer Lett; 2017 Aug; 400():9-17. PubMed ID: 28450158
[TBL] [Abstract][Full Text] [Related]
29. Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling.
Wandinger SK; Lahortiga I; Jacobs K; Klammer M; Jordan N; Elschenbroich S; Parade M; Jacoby E; Linders JT; Brehmer D; Cools J; Daub H
PLoS One; 2016; 11(1):e0146100. PubMed ID: 26745281
[TBL] [Abstract][Full Text] [Related]
30. The ErbB3-binding protein EBP1 modulates lapatinib sensitivity in prostate cancer cells.
Awasthi S; Ezelle H; Hassel BA; Hamburger AW
Mol Cell Biochem; 2015 Jul; 405(1-2):177-86. PubMed ID: 25876877
[TBL] [Abstract][Full Text] [Related]
31. Cytoplasmic, full length and novel cleaved variant, TBLR1 reduces apoptosis in prostate cancer under androgen deprivation.
Daniels G; Zhang X; Zhong X; Santiago L; Wang LH; Wu X; Zhang JY; Liang F; Li X; Neubert TA; Steinke L; Shen Y; Basch R; Schneider R; Levy DE; Lee P
Oncotarget; 2016 Jun; 7(26):39556-39571. PubMed ID: 27127173
[TBL] [Abstract][Full Text] [Related]
32. High-Content Screening Identifies Src Family Kinases as Potential Regulators of AR-V7 Expression and Androgen-Independent Cell Growth.
Szafran AT; Stephan C; Bolt M; Mancini MG; Marcelli M; Mancini MA
Prostate; 2017 Jan; 77(1):82-93. PubMed ID: 27699828
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of ERBB family mRNA expression in breast carcinomas.
Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
[TBL] [Abstract][Full Text] [Related]
34. Restoration of fibroblast growth factor receptor 2IIIb enhances the chemosensitivity of human prostate cancer cells.
Shoji K; Teishima J; Hayashi T; Ohara S; Mckeehan WL; Matsubara A
Oncol Rep; 2014 Jul; 32(1):65-70. PubMed ID: 24839986
[TBL] [Abstract][Full Text] [Related]
35. Long noncoding RNA MALAT-1 is a new potential therapeutic target for castration resistant prostate cancer.
Ren S; Liu Y; Xu W; Sun Y; Lu J; Wang F; Wei M; Shen J; Hou J; Gao X; Xu C; Huang J; Zhao Y; Sun Y
J Urol; 2013 Dec; 190(6):2278-87. PubMed ID: 23845456
[TBL] [Abstract][Full Text] [Related]
36. Identification of novel genes that regulate androgen receptor signaling and growth of androgen-deprived prostate cancer cells.
Levina E; Ji H; Chen M; Baig M; Oliver D; Ohouo P; Lim CU; Schools G; Carmack S; Ding Y; Broude EV; Roninson IB; Buttyan R; Shtutman M
Oncotarget; 2015 May; 6(15):13088-104. PubMed ID: 26036626
[TBL] [Abstract][Full Text] [Related]
37. Autocrine Activation of CHRM3 Promotes Prostate Cancer Growth and Castration Resistance via CaM/CaMKK-Mediated Phosphorylation of Akt.
Wang N; Yao M; Xu J; Quan Y; Zhang K; Yang R; Gao WQ
Clin Cancer Res; 2015 Oct; 21(20):4676-85. PubMed ID: 26071486
[TBL] [Abstract][Full Text] [Related]
38. PADI2-Mediated Citrullination Promotes Prostate Cancer Progression.
Wang L; Song G; Zhang X; Feng T; Pan J; Chen W; Yang M; Bai X; Pang Y; Yu J; Han J; Han B
Cancer Res; 2017 Nov; 77(21):5755-5768. PubMed ID: 28819028
[TBL] [Abstract][Full Text] [Related]
39. EGF receptor inhibitors increase ErbB3 mRNA and protein levels in breast cancer cells.
Grøvdal LM; Kim J; Holst MR; Knudsen SL; Grandal MV; van Deurs B
Cell Signal; 2012 Jan; 24(1):296-301. PubMed ID: 21951604
[TBL] [Abstract][Full Text] [Related]
40. Characterizing the molecular features of ERG-positive tumors in primary and castration resistant prostate cancer.
Roudier MP; Winters BR; Coleman I; Lam HM; Zhang X; Coleman R; Chéry L; True LD; Higano CS; Montgomery B; Lange PH; Snyder LA; Srivastava S; Corey E; Vessella RL; Nelson PS; Üren A; Morrissey C
Prostate; 2016 Jun; 76(9):810-22. PubMed ID: 26990456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
